Urinary tract infections due to extended-spectrum beta-lactamase-producing Gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary referral hospital

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Michael OsthoffDamon P Eisen

Abstract

Extended-spectrum beta-lactamase-expressing Gram-negative bacilli (ESBL-GNB) now commonly cause community-acquired infections, including urinary tract infections (UTI), and represent a challenge for practitioners in choosing empirical antibiotics. The aim of this study was to describe the epidemiology and clinical characteristics of UTIs/bacteriuria due to ESBL-GNB in Australia. At a single-site tertiary referral hospital, 100 cases with UTIs/bacteriuria due to ESBL-GNB were matched to 100 cases where UTIs/bacteriuria were caused by organisms matching the ESBL bacterial species that had routine susceptibility to antibiotics. Potential risk factors for ESBL-GNB UTI/bacteriuria and differences in clinical outcomes were identified. Length of admission prior to positive sample (odds ratio (OR) 1.3, p = 0.03, per week), exposure to antibiotics (OR 5.7, p < 0.001), return from overseas travel (OR 6.5, p = 0.002), and nursing home residency (OR 4.2, p = 0.03) were identified as risk factors associated with ESBL-GNB UTI/bacteriuria in the multivariate analysis. In addition, ESBL-GNB-infected cases subsequently had a longer inpatient stay (median 6 vs. 2 days, p = 0.002) and were admitted to the intensive care unit more frequently (28/1...Continue Reading

References

Oct 24, 1998·The Journal of Antimicrobial Chemotherapy·W Brumfitt, J M Hamilton-Miller
Feb 27, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R ColodnerR Raz
Feb 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lindsay E NicolleUNKNOWN American Geriatric Society
Jun 19, 2009·Current Drug Safety·Emilia HardakMordechai Yigla
Sep 14, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K Kennedy, P Collignon
Nov 9, 2011·The Medical Journal of Australia·Rhonda L StuartTony M Korman
Mar 7, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B A RogersD L Paterson
Aug 29, 2012·Antimicrobial Agents and Chemotherapy·Elizabeth A NeunerDavid van Duin
Oct 9, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Sarah Tschudin-SutterAndreas Franz Widmer
Feb 4, 2014·The Medical Journal of Australia·Kyra Y L ChuaBenjamin P Howden

❮ Previous
Next ❯

Citations

Dec 25, 2015·Current Infectious Disease Reports·Joseph B CanteySarah M McCormick
Apr 27, 2016·Enfermedades infecciosas y microbiología clínica·Natalia Chacón-MoraElisa Cordero Matía
Sep 15, 2016·Revista latino-americana de enfermagem·Anna Letícia MirandaCynthia Adalgisa Mesojedovas Aguiar
Feb 15, 2019·BMC Infectious Diseases·Helena Kornfält IsbergAnders Beckman
May 23, 2020·The Journal of Antimicrobial Chemotherapy·Adam G StewartDavid L Paterson
Mar 27, 2018·International Journal of Nursing Practice·Hui Ang, Xuan Sun
Jun 3, 2017·Applied Biochemistry and Biotechnology·Rajamohamed Beema ShafreenSulaiman Ali Alharbi
Feb 23, 2019·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Aurélien Emmanuel MartinezSarah Tschudin-Sutter
May 19, 2017·Journal of Travel Medicine·Paul-Louis WoertherAnu Kantele
Jul 1, 2018·Current Infectious Disease Reports·Kevin L Schwartz, Shaun K Morris
Oct 17, 2018·Journal of Paediatrics and Child Health·Jus RakhraHasantha Gunasekera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

Enfermedades infecciosas y microbiología clínica
Mariam NoureddineGrupo para el Estudio de las Infecciones Cardiovasculares de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale
Marianna Ofner-AgostiniElizabeth Bryce
© 2021 Meta ULC. All rights reserved